Search

Meeting Coverage:

American Academy of Ophthalmology

AAO: 2017

Head-to-Head Trials

Pravin Dugel, MD

Show Description +

Pravin Dugel, MD, examines data from the HAWK and HARRIER studies, evaluating the efficacy of brolucizumab (RTH258, Novartis) compared with aflibercept (Eylea, Regeneron) in the treatment of patients with neovascular age-related macular degeneration (AMD) in a matched, direct, head-to-head comparison over a period of 48 weeks. Dr. Dugel discusses the performance of the drugs during disease activity assessments at week 16 and scheduled at prespecified times thereafter, and he considers the role of brolucizumab in disease control and in more sustainable treatment strategies moving forward.

Posted: 11/17/2017

Keywords:

HAWK and HARRIER

•

Retina Subspecialty Day

Up Next

Who, What, Where, and When?

Who, What, Where, and When?

Arsham Sheybani, MD, Ike Ahmed, MD

An Update on GATT

An Update on GATT

Davinder Grover, MD

Managing Uveitic Glaucoma

Managing Uveitic Glaucoma

Allen Beck, MD

Glaucoma: A Two-Pressure Disease?

Glaucoma: A Two-Pressure Disease?

John Berdahl, MD

Who Should Perform MIGS?

Who Should Perform MIGS?

Michael Patterson, DO

Iris Prostheses: From Bench to Bedside

Iris Prostheses: From Bench to Bedside

Michael Snyder, MD

Hot Topic: Is Astigmatism Correction a Must?

Hot Topic: Is Astigmatism Correction a Must?

George Waring IV, MD, Neel Desai, MD, Zaina Al-Mohtaseb, MD

Updates on Sjögren Syndrome

Updates on Sjögren Syndrome

Stephen Pflugfelder, MD

Treatment Options in Patients With Chronic DME

Treatment Options in Patients With Chronic DME

Nathan Radcliffe, MD

Who Should Perform MIGS?

Who Should Perform MIGS?

Osamah Saeedi, MD

The Application of Meibography Imaging to Detect DED

The Application of Meibography Imaging to Detect DED

Jennifer Loh, MD

Hot Topic: Technologies in 2018

Hot Topic: Technologies in 2018

Robert Weinstock, MD, Roger Zaldivar, MD

The Future of Cross-linking

The Future of Cross-linking

William Trattler, MD

A Diagram for Posterior Capsule Rupture

A Diagram for Posterior Capsule Rupture

Ashvin Agarwal, MD

Should We Still Be Doing DSAEK?

Should We Still Be Doing DSAEK?

Winston Chamberlain, MD, PhD

Combating Patient Dissatisfaction After Multifocal IOL Implantation

Combating Patient Dissatisfaction After Multifocal IOL Implantation

John Berdahl, MD

Hot Topic: Pharmaceutical Compounding

Hot Topic: Pharmaceutical Compounding

Keith Walter, MD, Nathan Radcliffe, MD, Tal Raviv, MD

A Pragmatic Approach to Surgical Evaluation

A Pragmatic Approach to Surgical Evaluation

Roger Zaldivar, MD, MS, MBA

Corneal Transplantation in the Era of Femtosecond Laser

Corneal Transplantation in the Era of Femtosecond Laser

Marjan Farid, MD

Pitfalls for Corneal Inlays in Presbyopic Patients

Pitfalls for Corneal Inlays in Presbyopic Patients

George Waring IV, MD

Hot Topic: Successful Collaborations

Hot Topic: Successful Collaborations

Constance Okeke, MD, Greg Parkhurst, MD, John Berdahl, MD

Next-Gen Sequencing in Uveal Melanoma

Next-Gen Sequencing in Uveal Melanoma

J. William Harbour, MD

Suprachoroidal Steroids for DME

Suprachoroidal Steroids for DME

Charles Wykoff, MD, PhD

DME Outcomes Following TREX

DME Outcomes Following TREX

David Brown, MD

Gene Therapy for Wet AMD

Gene Therapy for Wet AMD

Szilárd Kiss, MD

Back to All Videos

Head-to-Head Trials

Pravin Dugel, MD

Pravin Dugel, MD, examines data from the HAWK and HARRIER studies, evaluating the efficacy of brolucizumab (RTH258, Novartis) compared with aflibercept (Eylea, Regeneron) in the treatment of patients with neovascular age-related macular degeneration (AMD) in a matched, direct, head-to-head comparison over a period of 48 weeks. Dr. Dugel discusses the performance of the drugs during disease activity assessments at week 16 and scheduled at prespecified times thereafter, and he considers the role of brolucizumab in disease control and in more sustainable treatment strategies moving forward.

Posted: 11/17/2017

Keywords:

HAWK and HARRIER

•

Retina Subspecialty Day

Please log in to leave a comment.

More From AAO: 2017 Coverage

Next-Gen Sequencing in Uveal Melanoma

Next-Gen Sequencing in Uveal Melanoma

J. William Harbour, MD

Suprachoroidal Steroids for DME

Suprachoroidal Steroids for DME

Charles Wykoff, MD, PhD

DME Outcomes Following TREX

DME Outcomes Following TREX

David Brown, MD

Gene Therapy for Wet AMD

Gene Therapy for Wet AMD

Szilárd Kiss, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2017.